NEW YORK (GenomeWeb) – The US Food and Drug Administration has granted 510(k) clearance and CLIA waiver to an assay for influenza and respiratory syncytial virus manufactured by Cepheid, the firm announced today.

The Xpert Flu+RSV Xpress test is the first point-of-care, CLIA-waived assay from Cepheid, and the first waived test on the market to detect and discriminate flu and RSV.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.